Stock comparison
LeMaitre Vascular
Supernus Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
SUPN
Supernus Pharmaceuticals
Market cap
$2.8B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | SUPN | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 20F | LMAT |
| Benjamin Graham | 89A | 43D | LMAT |
| Philip Fisher |
Side-by-side metrics
| Metric | LMAT | SUPN |
|---|---|---|
| Market cap | $2.23B | $2.8B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -2.16% |
| Gross margin | 72.39% | 89.42% |
| Net margin | 24.35% | -3.74% |
| Revenue CAGR 5y | 12.75% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- ROIC (TTM)9.43%vs -2.16%+123%
- Net margin24.35%vs -3.74%+115%
- Dividend yield0.84%vs 0.0%+100%
- Revenue CAGR 5y12.75%vs 5.53%
More like SUPN
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.